source
- FDA advisory panel to consider reclassifying several widely used peptidesAn FDA advisory committee is meeting this week to decide whether it will recommend reclassifying a group of popular peptide products. The discussion comes as the industry watches closely for any sh…
- Eli Lilly’s $3.8 B bid for AtaiBeckley signals strong pharma endorsement of psychedelicsEli Lilly has announced a proposed acquisition of AtaiBeckley valued at up to $3.8 billion. Analysts at H.C. Wainwright described the move as the clearest strategic validation to date of psychedeli…